Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 474 results for "adap"

Adaptimmune's TCR candidate shows encouraging activity in Phas...

News Editor Data from a 20-subject Phase 1/2 clinical trial assessing Adaptimmune's (ADAP -5.9%) T-cell receptor (TCR) therapeutic candidate, NY-ESO-1, in patients with multiple myeloma show an encouraging antitumor effect. The results were ... Seeking Alpha, 1 week ago
Securities Technology Monitor

Adaptimmune's NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence, Clinical Activity and Tolerability in Clinical Study in Multiple Myeloma Patients

(GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that data from its Phase I/II study of its affinity enhanced T-cell ...
 Consumer Electronics Net1 week ago Argos Therapeutics Announces Completion of Patient Enrollment in Pivotal Phase 3 ADAP...  CNN Money2 weeks ago Adaptimmune's IND Application for MAGE-A10 Accepted  Zacks.com3 weeks ago Adaptimmune Announces FDA Acceptance of Investigational New Drug (IND) Application for MAGE-A10 T in Patients With Non-Small Cell Lung Cancer  Yahoo! Finance1 month ago

VRTX Drug Gets Approval, AGTC Surges On Biogen Deal, PFE Gets A Date With FDA

Adaptimmune Therapeutics plc (ADAP) is all set to initiate an open label phase I/II study of its wholly-owned MAGE-A10 T therapeutic candidate in patients with non-small cell lung cancer, following the acceptance of the company's investigational new ...
 RTTNews.com4 weeks ago

Adaptimmune: FDA Accepts IND For MAGE-A10 T - Quick Facts

Adaptimmune Therapeutics plc (ADAP) announced the U.S. FDA has accepted the company's investigational new drug application for autologous genetically modified T-cells expressing enhanced T cell receptors specific for MAGE A10 in patients with ...
 RTTNews.com1 month ago
Mideast Time

Analysts Set $22.00 Price Target for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)

Adaptimmune Therapeutics PLC (NASDAQ:ADAP) has received an average broker rating score of 1.67 (Buy) from the three brokers that provide coverage for the company, Zacks Investment Research reports. One equities research analyst has rated the stock ...
 SleekMoney1 week ago Zacks: Brokerages Set $22.00 Target Price for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)  WKRB News3 weeks ago Adaptimmune Therapeutics PLC -s Buy Rating Reiterated at Leerink Swann (ADAP)  WKRB News4 weeks ago Adaptimmune Therapeutics PLC Given Buy Rating at Leerink Swann (ADAP)  Ticker Report1 month ago

Mid-Day Changers: Adaptimmune Therapeutics plc (ADAP), Chiasma, Inc (CHMA), B2Gold Corp. (BTG), NRG Yield, Inc. (NYLD-A), Egalet Corporation (EGLT)

WallStreet Scope July 31st, 2015: Mid Day Changers Adaptimmune Therapeutics plc ( ADAP ) of the Healthcare sector has changed by 3.38% and at noon is trading with a volume of 25,952 shares with a volatility this week of 9.68%. Adaptimmune ...
 WallStreetScope.com1 day ago Most Volatile Stocks: Adaptimmune Therapeutics plc (ADAP), Penn West Petroleum Ltd. (PWE), Enzon Pharmaceuticals Inc. (ENZN), Infosonics Corp. (IFON), Synthetic Biologics Inc. (SYN)  WallStreetScope.com5 days ago Most Volatile Stocks: Epizyme, Inc. (EPZM), Adaptimmune Therapeutics plc (ADAP), Datawatch Corporation (DWCH), VMware, Inc. (VMW), CytRx Corporation (CYTR)  WallStreetScope.com1 week ago Adaptimmune Therapeutics PLC -s Quiet Period To Expire Tomorrow (NASDAQ:ADAP)  Mideast Time1 month ago

Private Insurance--and ADAP--Tied to Undetectable Viral Load in US Women

IAS 2015: 8th IAS Conference on HIV Pathogenesis Treatment and Prevention Vancouver, Canada 18-22 July 2015 IAS 2015, July 19-22, 2015, Vancouver ......."using ADAP independently lowered risk of unsuppressed viral load in women with no ...
 National AIDS Treatment Advocacy Project3 days ago

European ADRs Gain as Tech Developers Edge Up

In the UK, microprocessor designer ARM ( ARMH ) rose by 3.8% while Adaptimmune Therapeutics ( ADAP ), a clinical-stage biopharmaceutical company, expanded by 2.3% and education and media company Pearson rose by 1.9% after announcing that it had ...
 Nasdaq1 week ago European ADRs Edge Up as Pharma Stocks Gain  Nasdaq2 weeks ago European ADRs Inch Down as Pharmaceutical Stocks Slide Lower  Nasdaq1 week ago European ADRs Gain Traction as Retail Stocks Surge  Nasdaq1 month ago

Adaptimmune touts a promising snapshot of TCRs for myeloma

T-cell pioneer Carl June Adaptimmune ( $ADAP ) posted a promising early glimpse of its potential in the TCR cancer drug arena, an up-and-coming arm of the engineered T-cell programs now in the clinic. Investigators are reporting that out of 20 ...
 FierceBiotech1 week ago
Ticker Report

Equities Research Analysts Ratings Reiterations for July, 2nd (AAPL, ABBV, ADAP, AEZS, AGTC, ALLY, AMBA, AMP, APOL, ATHN)

Equities Research Analysts ratings reiterations for Thursday, July 2nd: Apple (NASDAQ:AAPL) had its hold rating reissued by analysts at KeyBanc. Apple (NASDAQ:AAPL) had its buy rating reaffirmed by analysts at Cantor Fitzgerald. AbbVie (NASDAQ:ABBV) ...
 Ticker Report1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less